Does long-term use of ticagrelor reduce the risk of cardiovascular death, myocardial infarction, or stroke in patients with a myocardial infarction more than 1 year previously?
Patients with a myocardial infarction more than 1 year previously
Ticagrelor (long-term use)
Composite of cardiovascular death, myocardial infarction, or strokecomposite
Long-term use of ticagrelor in patients with a prior myocardial infarction (>1 year) reduces ischemic events but increases the risk of major bleeding.
In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Bonaca et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69cea11e5ff5f19319758b5b — DOI: https://doi.org/10.1056/nejmoa1500857
Marc P. Bonaca
Deepak L. Bhatt
Marc Cohen
New England Journal of Medicine
Harvard University
Brigham and Women's Hospital
Inserm
Building similarity graph...
Analyzing shared references across papers
Loading...